A claim about a medicine's ingredients can be checked more directly than a claim about the intentions of its manufacturer. Start with the named product, its active substance and its prescribing information. For Ozempic, that substance is semaglutide.
The manufacturer's description identifies semaglutide as an analogue of human GLP-1 and says its peptide backbone is made using yeast fermentation. Venom does not appear in the ingredient list. That is the relevant evidence when assessing the suggestion, raised in the linked Bryan Ardis presentation, that Ozempic contains Gila monster venom.
▶ Watch the presentation on YouTube
There is a real lizard connection elsewhere in the history of diabetes research. NIDDK describes how work on a Gila monster protein, exendin-4, helped lead to exenatide. Exenatide and semaglutide are different medicines. A biological clue that inspires drug development is also different from the finished product's ingredient list.
Accurate correction should leave room for legitimate safety questions. Ozempic has contraindications, warnings and adverse effects described in its label. The useful discussion with a prescriber concerns those documented risks, the reason for treatment and the individual's circumstances. A dramatic origin story cannot answer those questions, and this video should not be used to change prescribed treatment without medical advice.
References
- Ozempic prescribing information, section 11: composition and manufacture
- NIDDK: the research history of GLP-1 medicines
- Bryan Ardis presentation: the commentary being examined
